Cocrystal Pharma Inc (COCP)vsNovartis AG ADR (NVS)
COCP
Cocrystal Pharma Inc
$0.96
-8.16%
HEALTHCARE · Cap: $14.20M
NVS
Novartis AG ADR
$148.38
-0.96%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 25145677% more annual revenue ($56.58B vs $225,000). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
COCP
Avoid23
out of 100
Grade: F
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+58.7%
Fair Value
$2.31
Current Price
$0.96
$1.35 discount
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 26.9% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : COCP
The strongest argument for COCP centers on Revenue Growth. Revenue growth of 26.9% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : COCP
The primary concerns for COCP are EPS Growth, Market Cap, Profit Margin.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
COCP profiles as a growth stock while NVS is a declining play — different risk/reward profiles.
COCP carries more volatility with a beta of 1.41 — expect wider price swings.
COCP is growing revenue faster at 26.9% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 23/100), backed by strong 23.9% margins. COCP offers better value entry with a 58.7% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cocrystal Pharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Cocrystal Pharma, Inc., a biotechnology company, is focused on the discovery and development of antiviral therapeutic treatments for serious and / or chronic viral diseases. The company is headquartered in Bothell, Washington.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?